Summary

Metered Dose Inhalers Market Research Report Information By Product (Press Metered Dose Inhalers, Breath Actuated Metered Dose Inhalers), By Propellant Type (HFA 134A, HFA 227EA, HFA 152A), By Technology (Pulmonary Platform Technologies, Nasal Platform Technologies), By Indication (Asthma, COPD, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) Market Forecast Till 2032

Market Overview
In 2023, the metered dose inhalers market was estimated to be worth USD 15.8 billion. The market is expected to expand from USD 17.1 billion in 2024 to USD 30.0 billion by 2032, with a compound annual growth rate (CAGR) of 6.43% for the forecast period (2024-2032). The global metered-dose inhaler market is developing due to rising respiratory illness prevalence, increased product releases by industry participants, and greater awareness and education.
The increasing availability of innovative metered dosage inhaler (MDI) products is a significant driver of growth in the worldwide MDI industry. These launches result in technology breakthroughs such as better drug delivery systems and ergonomic designs that cater to patient preferences for ease of use and adherence. Novel formulations and combinations provide more therapeutic choices for several respiratory disorders, thereby enhancing therapy efficacy and patient outcomes. Competitive dynamics among pharmaceutical companies stimulate innovation and cost, giving healthcare professionals and consumers access to a broader selection of high-quality MDI options. Furthermore, strategic market expansion into new geographies and focused solutions for specific patient populations fuel market growth, making MDI products essential in the global management of respiratory disorders.

Market Segment insights
The Metered Dose Inhalers Market is divided into two product categories: press metered dose inhalers and breath-actuated metered dose inhalers.
The Metered Dose Inhalers Market is divided into three segments based on propellant type: HFA-134a, HFA-227ea, and HFA-152a.
The Metered Dose Inhalers Market has been divided into two segments based on technology: pulmonary and nasal platform technologies.
According to indication, the Metered Dose Inhalers Market is divided into Asthma, COPD, and others.
The Metered Dose Inhalers Market is divided into three distribution channels: hospital pharmacies, retail pharmacies, and online pharmacies.

Regional insights
North America held the biggest market share in 2023. However, Asia-Pacific is expected to develop at the fastest CAGR throughout the forecast period (2024-2032).
The North American Metered Dose Inhalers market is expanding rapidly, owing to technical improvements, a favorable regulatory environment, and rising healthcare demands. Furthermore, the market is being driven by advanced healthcare infrastructure and significant expenditure in research and development, which has enabled the development of cutting-edge Metered Dose Inhalers.
The Americas region is followed by Europe, which is further divided into Germany, France, the United Kingdom, Italy, Spain, and the Rest of Europe. The Metered Dose Inhalers market in Europe is characterized by rising healthcare spending and a well-developed healthcare infrastructure.
Asia-Pacific is likely to grow significantly, becoming the fastest growing region throughout the forecast period, with substantial growth driven by a number of major factors. Rapidly expanding healthcare infrastructure and increased investment in healthcare infrastructure in nations such as China, India, and Japan are driving demand for sophisticated inhalers.

Major Players
AstraZeneca (UK), GSK PLC (UK), Organon (US), Cipla, Inc. (India), Lupin Pharmaceuticals, Inc. (India), Zydus Group (India), Teva Pharmaceutical Industries Ltd. (Israel), Viatris Inc. (US), Aristopharma Ltd. (Bangladesh), and Beximco Pharmaceuticals Limited (Bangladesh) are among the key players in the Metered Dose Inhalers Market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 INCREASING PRODUCT LAUNCH BY MARKET PLAYERS
4.2.2 GROWING AWARENESS AND EDUCATION
4.3 RESTRAINTS
4.3.1 VOLUNTARY PRODUCT RECALL FROM MARKET PLAYERS
4.3.2 STRINGENT REGULATORY POLICIES
4.4 OPPORTUNITY
4.4.1 INCREASING INVESTMENT BY PRIVATE AND PUBLIC ORGANIZATION
4.4.2 ONGOING CLINICAL TRIALS ASSOCIATED WITH METERED DOSE INHALER
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL METERED DOSE INHALERS MARKET
5.3 KEY TRENDS FOR GLOBAL METERED DOSE INHALERS MARKET
6 GLOBAL METERED DOSE INHALERS MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 PRESS METERED DOSE INHALERS
6.3 BREATH ACTUATED METERED DOSE INHALERS
7 GLOBAL METERED DOSE INHALERS MARKET, BY PROPELLANT TYPE
7.1 OVERVIEW
7.2 HFA 134A
7.3 HFA 227EA
7.4 HFA-152A
8 GLOBAL METERED DOSE INHALERS MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 PULMONARY PLATFORM TECHNOLOGIES
8.3 NASAL PLATFORM TECHNOLOGIES
9 GLOBAL METERED DOSE INHALERS MARKET, BY INDICATION
9.1 OVERVIEW
9.2 ASTHMA
9.3 COPD
9.4 OTHERS
10 GLOBAL METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACIES
10.3 RETAIL PHARMACIES
10.4 ONLINE PHARMACIES
11 GLOBAL METERED DOSE INHALER MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 FRANCE
11.3.3 UK
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 INDIA
11.4.3 JAPAN
11.4.4 SOUTH KOREA
11.4.5 AUSTRALIA
11.4.6 REST OF ASIA-PACIFIC
11.5 REST OF THE WORLD
11.5.1 MIDDLE EAST & AFRICA
11.5.2 SOUTH AMERICA
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 MARKET SHARE ANALYSIS, 2023
12.3 COMPETITOR DASHBOARD
12.4 PUBLIC PLAYERS STOCK SUMMARY
12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
12.6.1 PARTNERSHIP
12.6.2 PRODUCT LAUNCH/PRODUCT APPROVAL
13 COMPANY PROFILES
13.1 ASTRAZENECA
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 PRODUCTS OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 GSK PLC
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCT OFFERED
13.2.4 KEY DEVELOPMENTS
13.2.5 SWOT ANALYSIS
13.2.6 KEY STRATEGIES
13.3 ORGANON GROUP OF COMPANIES
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL OVERVIEW
13.3.3 PRODUCTS OFFERED
13.3.4 KEY DEVELOPMENTS
13.3.5 KEY STRATEGIES
13.4 CIPLA INC.
13.4.1 COMPANY OVERVIEW
13.4.2 FINANCIAL OVERVIEW
13.4.3 PRODUCTS OFFERED
13.4.4 KEY DEVELOPMENTS
13.4.5 SWOT ANALYSIS
13.4.6 KEY STRATEGIES
13.5 LUPIN PHARMACEUTICALS, INC.
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 PRODUCT OFFERED
13.5.4 KEY DEVELOPMENTS
13.5.5 SWOT ANALYSIS
13.5.6 KEY STRATEGIES
13.6 ZYDUS GROUP
13.6.1 COMPANY OVERVIEW
13.6.2 FINANCIAL OVERVIEW
13.6.3 PRODUCTS OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 KEY STRATEGIES
13.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL OVERVIEW
13.7.3 PRODUCTS OFFERED
13.7.4 KEY DEVELOPMENTS
13.7.5 SWOT ANALYSIS
13.7.6 KEY STRATEGIES
13.8 VIATRIS INC.
13.8.1 COMPANY OVERVIEW
13.8.2 FINANCIAL OVERVIEW
13.8.3 PRODUCTS OFFERED
13.8.4 KEY DEVELOPMENTS
13.8.5 SWOT ANALYSIS
13.8.6 KEY STRATEGIES
13.9 ARISTOPHARMA LTD.
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL OVERVIEW
13.9.3 PRODUCT OFFERED
13.9.4 KEY DEVELOPMENTS
SOURCE: ANNUAL REPORT AND PRESS RELEASES
13.9.5 KEY STRATEGIES
13.10 BEXIMCO PHARMACEUTICALS LTD.
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL OVERVIEW
13.10.3 PRODUCTS OFFERED
13.10.4 KEY DEVELOPMENTS
13.10.5 KEY STRATEGIES
13.11 DATA CITATIONS